You are here

  • Home
  • Archive
  • Volume 15, Issue 3
  • Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

Article Text

Article menu
Download PDFPDF
Therapeutics
Women's Health Initiative randomised ontrolled trial
Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

https://doi.org/10.1136/ebm1079

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests SMH is coordinating investigator of the KEEPS trial, where the study drugs are donated by Bayer Health Care Pharmaceuticals (Climara® patch) and Solvay Pharmaceuticals (Prometrium®)